NASDAQ · KALV
KalVista Pharmaceuticals, Inc.
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
NASDAQ · AKBA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Akebia Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Akebia Therapeutics, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akebia Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $0.03+200.0% vs estimate | $57.34M+12.87% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -$0.10-100.0% vs estimate | $46.50M+24.28% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.10-100.0% vs estimate | $37.43M-8.51% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $1.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$14.00$0.00 (0.0%)
Ventyx Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.0% below the high.
$51.45+$0.71 (+1.4%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$7.33-$0.16 (-2.14%)
Olema Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.78% below the high.
$10.36+$0.05 (+0.48%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.12% below the high.
$8.88-$0.22 (-2.42%)
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
